Cargando…

Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder

BACKGROUND: To examine potential differences in efficacy and safety of treatment with olanzapine in patients with schizophrenia of white and black descent. METHODS: A post-hoc, pooled analysis of 6 randomized, double-blind trials in the treatment of schizophrenia, schizophreniform disorder, or schiz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stauffer, Virginia L, Sniadecki, Jennifer L, Piezer, Kevin W, Gatz, Jennifer, Kollack-Walker, Sara, Hoffmann, Vicki Poole, Conley, Robert, Durell, Todd
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020682/ https://www.ncbi.nlm.nih.gov/pubmed/21047395 http://dx.doi.org/10.1186/1471-244X-10-89

Ejemplares similares

Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder
por: Lipkovich, Ilya, et al.
Publicado: (2008)

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder
por: Deberdt, Walter, et al.
Publicado: (2008)

S226. A STUDY COMPARING WEIGHT GAIN FROM ALKS 3831 TO OLANZAPINE IN EARLY-ILLNESS YOUNG ADULTS WITH SCHIZOPHRENIFORM, SCHIZOPHRENIA, OR BIPOLAR I DISORDER
por: Simmons, Adam, et al.
Publicado: (2018)

Hypocalcemia Masquerading as Schizophreniform Disorder
por: Mehta, Shivangi, et al.
Publicado: (2016)

The heterogeneity of antipsychotic response in the treatment of schizophrenia
por: Case, M., et al.
Publicado: (2011)

Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis
por: Stauffer, Virginia L, et al.
Publicado: (2009)

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
por: Ruberg, Stephen J, et al.
Publicado: (2011)

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians
por: Chen, Jian, et al.
Publicado: (2011)

Neurophysiological Distinction between Schizophrenia and Schizoaffective Disorder
por: Mathalon, Daniel H., et al.
Publicado: (2010)

HETEROGENEITY IN PLASMA HOMOVANILLIC ACID LEVELS IN SCHIZOPHRENIFORM DISORDER
por: Pradhan, N., et al.
Publicado: (1992)

Efficacy and Tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Chavda, R.K., et al.
Publicado: (2004)

The potential role of appetite in predicting weight changes during treatment with olanzapine
por: Case, Michael, et al.
Publicado: (2010)

Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder
por: Archibald, Luke, et al.
Publicado: (2019)

Myoclonic Jerks and Schizophreniform Syndrome: Case Report and Literature Review
por: Endres, Dominique, et al.
Publicado: (2018)

Clinical factors affecting functioning in patients with schizophrenia or schizoaffective disorder
por: Neily, C., et al.
Publicado: (2022)

The use of technologies and social media in patients with schizophrenia and schizoaffective disorder
por: Elleuch, O., et al.
Publicado: (2022)

Efficacy and tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Andrade, Chittaranjan
Publicado: (2004)

Measuring Emotional Awareness in Patients With Schizophrenia and Schizoaffective Disorders
por: Maaßen, Eva, et al.
Publicado: (2021)

Impairment in delay discounting in schizophrenia and schizoaffective disorder but not primary mood disorders
por: Brown, Hannah E., et al.
Publicado: (2018)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
por: Ye, Wenyu, et al.
Publicado: (2012)

Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study
por: McDonnell, David P., et al.
Publicado: (2014)

microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder
por: Perkins, Diana O, et al.
Publicado: (2007)

The continuing story of schizophrenia and schizoaffective disorder: One condition or two?
por: Hartman, Leah I., et al.
Publicado: (2019)

Religious Coping Strategies for Religious Patients with Schizophrenia and Schizoaffective Disorder
por: Gedevani, E., et al.
Publicado: (2022)

Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder
por: Amann, B. L., et al.
Publicado: (2015)

Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder
por: Mazumder, Atiqul Haq, et al.
Publicado: (2021)

Graves’ Thyrotoxicosis Presenting as Schizophreniform Psychosis: A Case Report and Literature Review
por: Ugwu, Ejiofor T., et al.
Publicado: (2016)

Effects of socio‐demographic characteristics, premorbid functioning, and insight on duration of untreated psychosis in first‐episode schizophrenia or schizophreniform disorder in Northern Malawi
por: Kaminga, Atipatsa C., et al.
Publicado: (2019)

Social function in schizophrenia and schizoaffective disorder: Associations with personality, symptoms and neurocognition
por: Lysaker, Paul H, et al.
Publicado: (2004)

Trauma and Posttraumatic Stress Disorder (PTSD) in Patients with Schizophrenia or Schizoaffective Disorder
por: Lommen, Miriam J. J., et al.
Publicado: (2009)

Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases
por: Min, Aran, et al.
Publicado: (2013)

Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder
por: Arion, Dominique, et al.
Publicado: (2015)

Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis
por: Fryar-Williams, Stephanie, et al.
Publicado: (2015)

The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
por: Ko, Young-Hoon, et al.
Publicado: (2014)

Evidence for Distinguishable Treatment Costs among Paranoid Schizophrenia and Schizoaffective Disorder
por: Hirjak, Dusan, et al.
Publicado: (2016)

Study of the Effect of Memantine on Negative Sign in Patients with Schizophrenia and Schizoaffective Disorders
por: Tavakoli-Ardakani, Maria, et al.
Publicado: (2018)

Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine
por: Kesserwani, Jad, et al.
Publicado: (2019)

Social and Neurocognitive Deficits in Remitted Patients with Schizophrenia, Schizoaffective and Bipolar Disorder
por: Dehelean, Liana, et al.
Publicado: (2021)

Cardiovascular Risk for Patients With and Without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder
por: Rossom, Rebecca C., et al.
Publicado: (2022)

Paroxetine combined with olanzapine in the treatment of schizophrenia
por: Wang, Ning, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rj9lrq045dgp52cgmn37sp6m0u